NewsAI-assisted

RGCB To Lead BioE3 Policy In Kerala: A Green Revolution Begins

India's BioE3 policy drives bio-economic growth, with Kerala's RGCB leading the shift to bio-manufacturing.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Aug 30, 2024Updated Jun 26, 2025 · 2 min read
RGCB To Lead BioE3 Policy In Kerala: A Green Revolution Begins
https://cityseeker.com/thiruvananthapuram/704438-rajiv-gandhi-centre-for-biotechnology
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

With the introduction of the BioE3 policy, India is set to lead the charge in the next industrial revolution. This initiative is expected to drive substantial investments in innovation, with the goal of boosting the bio-economic sector to reach a target of Rs 25 lakh crore by 2030. In Kerala, the Rajiv Gandhi Centre for Biotechnology (RGCB) is spearheading efforts to shift from traditional chemical-based industries to bio-manufacturing centers. 

These centers are designed to bolster the nation’s economy while addressing crucial issues related to food, energy, and climate change. Dr. Chandrabhas Narayana, director of RGCB in Thiruvananthapuram, commended the move towards bio-manufacturing hubs. He shared that RGCB plans to launch awareness campaigns across Kerala to inform various stakeholders about the BioE3 policy.

In a panel discussion with senior officials from the Department of Science and Technology (DST) on Thursday, RGCB reaffirmed its commitment to guiding Kerala in the rollout of this transformative policy. Approved last weekend, the BioE3 policy aims to harness the power of bio-manufacturing to foster a cleaner, greener India. The state-wide initiative, which includes workshops and discussions on BioE3, has been launched to emphasize the policy’s critical role in advancing the country’s carbon neutrality goals.

 

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →